Document Classification

Section Type: RESULTS

Text: In carriers of the CYP2C19 * 1/CYP2C19 * 1 and CYP2C19 * 1/CYP2C19 * 2 or * 3 genotype, allicin treatment increased the peak plasma concentration (C (max)) of omeprazole by 49. 7 + / - 7. 2 (p < 0. 001) and 54. 2 + / - 9. 2 % (p < 0. 001), and increased the area under the plasma time-concentration curve (AUC (0-infinity)) of omeprazole by 48. 1 + / - 9. 0 (p = 0. 001) and 73. 6 + / - 26. 7 % (p < 0. 001), respectively.